EA7211: A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
Enrolling By Invitation
99 years or below
All
Phase
N/A
1 Location
Brief description of study
The primary objective of this study is to assess whether preoperative hemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of patients with high risk de-differentiated liposarcoma DDLPS) and leiomyosarcoma (LMS) as measured by disease-free survival.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 855077
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
